ArticleAnnals of Indian Academy of Neurology2026
Magnetic Resonance Imaging-Negative Lupus Myelitis: A Narrative Review.
Article in Annals of Indian Academy of Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractMagnetic resonance imaging (MRI)-negative lupus myelitis (MNLM) is a rare neurological manifestation of systemic lupus erythematosus (SLE). Diagnosing MNLM without prior systemic involvement remains challenging. This review aims to analyze all published cases and compare MNLM patients with (Group A) and without prior SLE diagnosis (Group B), emphasizing on demographic and clinical profiles, treatment, and outcomes. A PubMed literature review on MNLM was conducted. Demographic profile, clinical presentations, and management were analyzed. MNLM patients were categorized into Group A and B and compared using univariate and multivariate comparison methods, where a P value <0.05 was considered significant. In total, 41 cases were analyzed. The cohort was predominantly female (8:1 ratio, mean age 31.22 ± 11.91 years, range 15-59 years). Thoracic cord involvement was the most common (55%), with myelitis presenting as the first manifestation in 49% of patients. Clinical presentations were predominantly subacute (71%) with partial tract involvement in 63%. Group A demonstrated significantly higher cervical cord localization ( P = 0.019) compared to Group B's thoracic involvement ( P = 0.041). Antiphospholipid syndrome (APS) antibody-positive patients showed 3.2-fold higher odds for partial recovery ( P = 0.16). Logistic regression analysis identified Anti Smith/ Ribonucleoprotein/ Ribosomal (Sm/RNP/Rib) antibodies as independent risk factors for poor complete recovery (odds ratio (OR) = 0.61), whereas cervical cord localization independently improved odds for complete recovery (OR = 3.2). MNLM presents with variable clinical manifestations suggesting selective tract involvement. Group A exhibits higher cervical involvement, while Group B shows predominantly thoracic involvement. APS antibodies favor partial recovery, cervical localization predicts complete recovery, and Sm/RNP/Rib antibodies are independent predictors of poor recovery outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.